10-K · February 26, 2026
Ingevity completed its Strategic Portfolio Review and closed the sale of the North Charleston CTO refinery and most of the industrial specialties product line (the Divestiture) on January 1, 2026, creating a simplified…
Earnings analysis · 10-Q
NGVT earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Ingevity Corporation's Q1 2026 results show significant outperformance with net sales of $258.0 million, up 4% from the prior year, and EPS of $1.15 eclipsing estimates of $0.83. However, while the Performance Materials…
Read full summary
Ingevity Corporation's Q1 2026 results show significant outperformance with net sales of $258.0 million, up 4% from the prior year, and EPS of $1.15 eclipsing estimates of $0.83. However, while the Performance Materials segment drove revenue growth, the Performance Chemicals segment posted flat sales and declining EBITDA. The company faces ongoing challenges from legal costs and restructuring but maintains an optimistic outlook for the year.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.15
- Segment
- Performance Materials
- Segment
- Performance Chemicals
- Segment
- Advanced Polymer Technologies
What stood out
-
Significant Revenue Growth
Net sales increased by 4% year-over-year to $258.0 million, up from $247.9 million in Q1 2025.
-
Strong EPS Beat
EPS reached $1.15, exceeding estimates of $0.83, marking a notable 38.55% surprise.
-
Performance Materials Robust Gain
The Performance Materials segment saw a 6% increase in net sales to $155.4 million, driven by pricing actions.
-
Declining Performance Chemicals Segment
Performance Chemicals reported flat sales at $58.3 million, with a 10% decline in Road Markings product line.
-
Improved Operating Margins
Gross margin improved to 45.1%, up from 45.0% in the prior year despite rising manufacturing costs.
-
Healthy Cash Flow from Investing Activities
Generates $106.3 million in cash from investing activities primarily driven by the sale of the industrial specialties product line.
What to watch
-
Legal Settlement Expenses
Incurred a $113.2 million cash outlay due to the BASF litigation settlement, affecting operations and liquidity.
-
Ongoing Restructuring Costs
Anticipates indirect costs of $12-18 million from divested product lines impacting margins in 2026.
-
Volatile Commodity Costs
Rise in raw material costs could squeeze margins, highlighted by a 10% increase in natural gas prices affecting $1.0 million in costs.
Management's outlook
Management reaffirms the previously disclosed outlook for 2026, excluding contributions from divested product lines.
Earlier filings 4
10-Q · May 6, 2025
Ingevity reported Q1 net sales of $284.0 million, down $56.1 million (-16.5%) from $340.1 million a year ago, but delivered a return to profitability with net income of $20.5 million and diluted EPS of $0.56 (versus a…
10-Q · October 30, 2024
Ingevity reported Q3 net sales of $376.9 million, down from $446.0 million a year earlier, and recorded a net loss of $107.2 million (diluted loss per share $2.95). Management took a non‑cash goodwill impairment of…
10-Q · August 1, 2024
Ingevity reported Q2 net sales of $390.6 million and GAAP diluted loss per share of $(7.81), missing consensus on both revenue and EPS. Results were materially affected by a $349.1 million non-cash goodwill impairment…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.